Anifrolumab
阿伏利尤单抗
Report date: 2026/05/15 20:01:45
First In Class
Base Information
Drug NameAnifrolumab
Drug Alias Name +[7]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications +[15]
Global Approved Indications
Approved Indications in China
Original Approved Country/Territory
Original Approved Date2021/07/30
Country/Territory +[48]
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMedimmune LlcMedarex Inc
China Registration ClassN/A
Develop Information
Active CompaniesUniversity Medical Center GroningenNational And Kapodistrian University Of AthensNational Institute Of Arthritis And Musculoskeletal And Skin Diseases +[9]
Inactive CompaniesMedimmune Llc
Active Indications +[14]
Inactive Indications